Recently, “Tolvaptan Tablets” (Brand name: Xinsuan), a new diuretic drug developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the People’s Republic of China and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs.

Recently, “Sunitinib Malate Capsules” (brand name: Qingnishu (晴尼舒)) (approved specification: 12.5mg), a key product in the field of oncology developed by the Group, has obtained the drug registration certificate from the National Medical Products Administration of the People’s Republic of China.

Recently, “Aprepitant Capsules” (brand name: “Shanyi” (善依)) (approved specifications: 80mg and 125mg), an adjuvant drug for tumor treatment developed by the Group, has obtained the drug registration certificate from the National Medical Products Administration of the People’s Republic of China.

Recently, “Dasatinib Tablet” (product name: Yinishu) (specifications: 20mg and 50mg), an oncology medicine developed by the Group, has obtained the notice of approval of supplemental application on pharmaceutical product issued by the National Medical Products Administration of the People’s Republic of China,